Free Trial

Humana (HUM) Stock Forecast & Price Target

Humana logo
$239.76 +1.80 (+0.75%)
Closing price 03:59 PM Eastern
Extended Trading
$239.68 -0.07 (-0.03%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Humana - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
4
Hold
15
Buy
7

Based on 26 Wall Street analysts who have issued ratings for Humana in the last 12 months, the stock has a consensus rating of "Hold." Out of the 26 analysts, 4 have given a sell rating, 15 have given a hold rating, and 7 have given a buy rating for HUM.

Consensus Price Target

$247.61
3.28% Upside
According to the 26 analysts' twelve-month price targets for Humana, the average price target is $247.61. The highest price target for HUM is $344.00, while the lowest price target for HUM is $146.00. The average price target represents a forecasted upside of 3.28% from the current price of $239.76.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for HUM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Humana and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HUM Analyst Ratings Over Time

TypeCurrent Forecast
5/5/25 to 5/5/26
1 Month Ago
4/5/25 to 4/5/26
3 Months Ago
2/4/25 to 2/4/26
1 Year Ago
5/5/24 to 5/5/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
Hold
15 Hold rating(s)
16 Hold rating(s)
9 Hold rating(s)
15 Hold rating(s)
Sell
4 Sell rating(s)
3 Sell rating(s)
5 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$247.61$225.48$293.21$287.76
Forecasted Upside3.28% Upside26.64% Upside52.60% Upside12.00% Upside
Consensus RatingHoldHoldHoldHold

HUM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HUM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Humana Stock vs. The Competition

TypeHumanaMedical CompaniesS&P 500
Consensus Rating Score
2.12
2.30
2.52
Consensus RatingHoldHoldModerate Buy
Predicted Upside3.94% Upside872.24% Upside15.38% Upside
News Sentiment Rating
Positive News

See Recent HUM News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
5/1/2026
TD Cowen logo
TD Cowen
3 of 5 stars
Ryan Langston
Ryan Langston
Not Rated
Boost TargetHold$173.00 ➝ $211.00-9.15%
5/1/2026 Reiterated RatingOutperform$260.00+9.77%
5/1/2026
Lisa Gill
Lisa Gill
3 of 5 stars
Boost TargetNeutral$180.00 ➝ $214.00-9.56%
4/30/2026Boost TargetSector Perform$189.00 ➝ $246.00+2.03%
4/30/2026 Reiterated RatingOutperform$260.00+7.23%
4/30/2026Boost TargetBuy$252.00 ➝ $269.00+10.26%
4/30/2026Boost TargetNeutral$195.00 ➝ $262.00+7.39%
4/30/2026Boost TargetEqual Weight$176.00 ➝ $180.00-26.22%
4/30/2026 Boost Target$195.00 ➝ $250.00+4.75%
4/30/2026 Boost Target$201.00 ➝ $264.00+10.62%
4/30/2026 Boost Target$258.00 ➝ $290.00+21.51%
4/30/2026 Boost Target$235.00 ➝ $290.00+21.51%
4/30/2026 Boost TargetSell$158.00 ➝ $195.00-18.29%
4/30/2026 Boost TargetMarket Perform$185.00 ➝ $255.00+6.85%
4/30/2026Boost TargetHold$220.00 ➝ $270.00+10.88%
4/30/2026 Boost TargetHold$180.00 ➝ $235.00-3.59%
4/21/2026 Reiterated RatingSell (D+)
4/15/2026 Lower TargetNeutral$264.00 ➝ $205.00+4.99%
4/14/2026 DowngradeHoldStrong Sell
4/7/2026Boost TargetEqual Weight$206.00 ➝ $227.00+18.04%
4/6/2026 Lower TargetOutperform$325.00 ➝ $250.00+24.05%
2/12/2026Set Target$146.00-16.74%
1/6/2026Reiterated RatingOutperform$344.00+24.57%
12/12/2025 Reiterated RatingSector Weight
10/10/2025Boost TargetNeutral$280.00 ➝ $300.00+5.92%
7/31/2025Lower TargetNeutral$288.00 ➝ $272.00+6.39%
10/9/2024Reiterated RatingEqual Weight$250.00 ➝ $250.00+2.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 04:16 PM ET.


Should I Buy Humana Stock? HUM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, May 4, 2026. Please send any questions or comments about these Humana pros and cons to contact@marketbeat.com.

Humana
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Humana Inc.:

  • Recent analyst upgrades have raised the price target for Humana Inc. to around $255, indicating a potential upside from the current stock price of approximately $235.
  • Humana Inc. has a strong market presence in the Medicare Advantage sector, which is expected to grow as the population ages, providing a stable revenue stream.
  • The company has reported a solid financial performance, with a market cap of $28.25 billion and a PE ratio that suggests growth potential compared to industry averages.
  • Humana Inc. is focusing on margin recovery and has plans to address cost pressures, which could enhance profitability in the coming quarters.
  • With a consensus rating of "Hold" from analysts, there is a balanced outlook that suggests stability while still allowing for potential growth opportunities.

Humana
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Humana Inc. for these reasons:

  • Management has indicated that Medicare payment updates are not keeping pace with rising costs, which could lead to margin pressures and affect profitability.
  • Despite recent earnings beats, the stock has faced downward pressure due to unchanged guidance and concerns over declining MA Star ratings, which impact quality bonuses.
  • There are mixed views among analysts regarding the company's growth potential versus near-term risks, reflected in the high number of "Hold" ratings.
  • Cost pressures remain a significant concern, as the company has acknowledged ongoing challenges that could hinder its financial performance in the short term.
  • Recent market reactions have shown volatility, with shares falling after earnings releases, indicating investor uncertainty about the company's future outlook.

HUM Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Humana is $247.61, with a high forecast of $344.00 and a low forecast of $146.00.

26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Humana in the last year. There are currently 4 sell ratings, 15 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HUM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HUM, but not buy additional shares or sell existing shares.

According to analysts, Humana's stock has a predicted upside of 3.28% based on their 12-month stock forecasts.

Over the previous 90 days, Humana's stock had 2 downgrades and 1 upgrade by analysts.

Analysts like Humana less than other "medical" companies. The consensus rating score for Humana is 2.12 while the average consensus rating score for "medical" companies is 2.30. Learn more on how HUM compares to other companies.


This page (NYSE:HUM) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners